Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension

Circulation

Volumn 133, Issue 20, 2016, Pages 1936-1944

  Brittain, Evan L ^a,b   Talati, Megha ^a   Fessel, Joshua P ^a   Zhu, He ^c   Penner, Niki ^a   Calcutt, M Wade ^a   West, James D ^a   Funke, Mitch ^a   Lewis, Gregory D ^d   Gerszten, Robert E ^d,e   Hamid, Rizwan ^a   Pugh, Meredith E ^a   Austin, Eric D ^a   Newman, John H ^a   Hemnes, Anna R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

fatty acids; heart ventricles; hypertension pulmonary; lipid metabolism; lipids; magnetic resonance spectroscopy; pulmonary circulation

Indexed keywords

ACYLCARNITINE; CERAMIDE; FATTY ACID; PALMITOYLCARNITINE; TRIACYLGLYCEROL;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE LIPOTOXICITY; HUMAN; HUMAN TISSUE; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPOTOXICITY; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PULMONARY HYPERTENSION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; COHORT ANALYSIS; HEART RIGHT VENTRICLE FUNCTION; HYPERTENSION, PULMONARY; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; TRANSGENIC MOUSE;

ANIMALS; CERAMIDES; COHORT STUDIES; FATTY ACIDS; HUMANS; HYPERTENSION, PULMONARY; MICE; MICE, TRANSGENIC; PROSPECTIVE STUDIES; TRIGLYCERIDES; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84961392285     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.019351     Document Type: Article

References (39)

1. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR, Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant 2011 30 904 911. doi: 10.1016/j.healun.2011.02.016
2. West J, Niswender KD, Johnson JA, Pugh ME, Gleaves L, Fessel JP, Hemnes AR, A potential role for insulin resistance in experimental pulmonary hypertension. Eur Respir J 2013 41 861 871. doi: 10.1183/09031936.00030312
3. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL, Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009 33 318 324. doi: 10.1183/09031936.00000508
4. Bokhari S, Raina A, Rosenweig EB, Schulze PC, Bokhari J, Einstein AJ, Barst RJ, Johnson LL, PET imaging may provide a novel biomarker and understanding of right ventricular dysfunction in patients with idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging 2011 4 641 647. doi: 10.1161/CIRCIMAGING.110.963207
5. Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED, Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2010 2 44ra58. doi: 10.1126/scitranslmed.3001327
6. Fang YH, Piao L, Hong Z, Toth PT, Marsboom G, Bache-Wiig P, Rehman J, Archer SL, Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle. J Mol Med (Berl) 2012 90 31 43. doi: 10.1007/s00109-011-0804-9
7. Opie LH, Knuuti J, The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009 54 1637 1646. doi: 10.1016/j.jacc.2009.07.024
8. Hemnes AR, Brittain EL, Trammell AW, Fessel JP, Austin ED, Penner N, Maynard KB, Gleaves L, Talati M, Absi T, Disalvo T, West J, Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 2014 189 325 334. doi: 10.1164/rccm.201306-1086OC
9. Gomez-Arroyo J, Mizuno S, Szczepanek K, Van Tassell B, Natarajan R, dos Remedios CG, Drake JI, Farkas L, Kraskauskas D, Wijesinghe DS, Chalfant CE, Bigbee J, Abbate A, Lesnefsky EJ, Bogaard HJ, Voelkel NF, Metabolic gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 2013 6 136 144. doi: 10.1161/CIRCHEARTFAILURE.111.966127
10. Piao L, Marsboom G, Archer SL, Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) 2010 88 1011 1020. doi: 10.1007/s00109-010-0679-1
11. Fessel JP, Hamid R, Wittmann BM, Robinson LJ, Blackwell T, Tada Y, Tanabe N, Tatsumi K, Hemnes AR, West JD, Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. Pulm Circ 2012 2 201 213. doi: 10.4103/2045-8932.97606
12. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB, Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013 62 25 suppl D42 D50. doi: 10.1016/j.jacc.2013.10.032
13. Kalim S, Clish CB, Wenger J, Elmariah S, Yeh RW, Deferio JJ, Pierce K, Deik A, Gerszten RE, Thadhani R, Rhee EP, A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc 2013 2 e000542. doi: 10.1161/JAHA.113.000542
14. Austin ED, Menon S, Hemnes AR, Robinson LR, Talati M, Fox KL, Cogan JD, Hamid R, Hedges LK, Robbins I, Lane K, Newman JH, Loyd JE, West J, Idiopathic and heritable PAH perturb common molecular pathways, correlated with increased MSX1 expression. Pulm Circ 2011 1 389 398. doi: 10.4103/2045-8932.87308
15. West JD, Austin ED, Gaskill C, Marriott S, Baskir R, Bilousova G, Jean JC, Hemnes AR, Menon S, Bloodworth NC, Fessel JP, Kropski JA, Irwin D, Ware LB, Wheeler L, Hong CC, Meyrick B, Loyd JE, Bowman AB, Ess KC, Klemm DJ, Young PP, Merryman WD, Kotton D, Majka SM, Identification of a common Wnt-Associated genetic signature across multiple cell types in pulmonary arterial hypertension. Am J Physiol Cell Physiol 2014 307 C415 C430. doi: 10.1152/ajpcell.00057.2014
16. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, Rodman DM, Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 2004 94 1109 1114. doi: 10.1161/01.RES.0000126047.82846.20
17. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS, Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007 116 1170 1175. doi: 10.1161/CIRCULATIONAHA.106.645614
18. Sutendra G, Michelakis ED, The metabolic basis of pulmonary arterial hypertension. Cell Metab 2014 19 558 573. doi: 10.1016/j.cmet.2014.01.004
19. Paulin R, Michelakis ED, The metabolic theory of pulmonary arterial hypertension. Circ Res 2014 115 148 164. doi: 10.1161/CIRCRESAHA.115.301130
20. Schooneman MG, Vaz FM, Houten SM, Soeters MR, Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 2013 62 1 8. doi: 10.2337/db12-0466
21. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, Bain J, Stevens R, Dyck JR, Newgard CB, Lopaschuk GD, Muoio DM, Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008 7 45 56. doi: 10.1016/j.cmet.2007.10.013
22. Brittain EL, Talati M, Zhu H, West J, Fessel JP, Penner N, Funke M, Lewis GD, Gerszten RE, Hamid R, Pugh ME, Austin ED, Newman JH, Hemnes AR, Dysregulated fatty acid metabolism in pulmonary arterial hypertension is associated with right ventricular steatosis and lipotoxicity. Circulation 2014 130 A18041. Abstract. http://circ.ahajournals.org/content/130/Suppl-2/A18041.abstract?sid=1aeecc98-6dbb-4360-A4e9-Ac3a83db9f21. Accessed September 3, 2015
23. Sutendra G, Dromparis P, Paulin R, Zervopoulos S, Haromy A, Nagendran J, Michelakis ED, A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl) 2013 91 1315 1327. doi: 10.1007/s00109-013-1059-4
24. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ, Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008 49 2101 2112. doi: 10.1194/jlr.M800147-JLR200
25. van de Weijer T, Schrauwen-Hinderling VB, Schrauwen P, Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res 2011 92 10 18
26. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH, Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000 97 1784 1789
27. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS, Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007 116 1170 1175. doi: 10.1161/CIRCULATIONAHA.106.645614
28. Reingold JS, Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Am J Physiol Endocrinol Metab 2005 289 E935 E939
29. van de Veerdonk MC, Kind T, Marcus JT, Mauritz GJ, Heymans MW, Bogaard HJ, Boonstra A, Marques KM, Westerhof N, Vonk-Noordegraaf A, Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol 2011 58 2511 2519
30. Amati F, Dubé JJ, Alvarez-Carnero E, Edreira MM, Chomentowski P, Coen PM, Switzer GE, Bickel PE, Stefanovic-Racic M, Toledo FG, Goodpaster BH, Skeletal muscle triglycerides, diacylglycerols, and ceramides in insulin resistance: another paradox in endurance-Trained athletes? Diabetes 2011 60 2588 2597. doi: 10.2337/db10-1221
31. Lysiak W, Toth PP, Suelter CH, Bieber LL, Quantitation of the efflux of acylcarnitines from rat heart, brain, and liver mitochondria. J Biol Chem 1986 261 13698 13703
32. McGarry JD, Mannaerts GP, Foster DW, A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 1977 60 265 270. doi: 10.1172/JCI108764
33. McGavock JM, Victor RG, Unger RH, Szczepaniak LS, American College of Physicians and the American Physiological Society Adiposity of the heart, revisited. Ann Intern Med 2006 144 517 524
34. Mahmod M, Bull S, Suttie JJ, Pal N, Holloway C, Dass S, Myerson SG, Schneider JE, De Silva R, Petrou M, Sayeed R, Westaby S, Clelland C, Francis JM, Ashrafian H, Karamitsos TD, Neubauer S, Myocardial steatosis and left ventricular contractile dysfunction in patients with severe aortic stenosis. Circ Cardiovasc Imaging 2013 6 808 816. doi: 10.1161/CIRCIMAGING.113.000559
35. Violante S, Ijlst L, Te Brinke H, Tavares de Almeida I, Wanders RJ, Ventura FV, Houten SM, Carnitine palmitoyltransferase 2 and carnitine/acylcarnitine translocase are involved in the mitochondrial synthesis and export of acylcarnitines. FASEB J 2013 27 2039 2044. doi: 10.1096/fj.12-216689
36. Piao L, Fang YH, Cadete VJ, Wietholt C, Urboniene D, Toth PT, Marsboom G, Zhang HJ, Haber I, Rehman J, Lopaschuk GD, Archer SL, The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) 2010 88 47 60. doi: 10.1007/s00109-009-0524-6
37. Piao L, Sidhu VK, Fang YH, Ryan JJ, Parikh KS, Hong Z, Toth PT, Morrow E, Kutty S, Lopaschuk GD, Archer SL, FOXO1-mediated upregulation of pyruvate dehydrogenase kinase-4 (PDK4) decreases glucose oxidation and impairs right ventricular function in pulmonary hypertension: therapeutic benefits of dichloroacetate. J Mol Med (Berl) 2013 91 333 346. doi: 10.1007/s00109-012-0982-0
38. Deaño RC, Glassner-Kolmin C, Rubenfire M, Frost A, Visovatti S, McLaughlin VV, Gomberg-Maitland M, Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med 2013 173 887 893. doi: 10.1001/jamainternmed.2013.319
39. Verzi MP, McCulley DJ, De Val S, Dodou E, Black BL, The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field. Dev Biol 2005 287 134 145. doi: 10.1016/j.ydbio.2005.08.041